HORSHAM, PA — Myonex, a leading global provider in this space, has agreed to acquire key business units of the France-based Creapharm Group. This acquisition encompasses Creapharm’s Clinical Packaging & Distribution and Commercial Packaging operations, as well as its bioservices, marking a pivotal expansion for Myonex into new territories and service areas.
Headquartered in Reims, France, with additional facilities in Bordeaux, Bailly-Romainvilliers, and an outpost in Marietta, Georgia, USA, Creapharm stands as a prominent player in clinical packaging and distribution. The integration of Creapharm into Myonex’s operations is poised to create a powerhouse in the clinical trial supply sector, offering a comprehensive suite of services that spans drug sourcing, clinical trial prescription services, clinical packaging, labeling, distribution, and advanced therapy medicinal products (ATMPs) supply chain management.
James Lovett, CEO of Myonex, emphasized the strategic benefits of the merger, highlighting the opportunity to bridge a market gap with a combination of extensive expertise, integrated services, and a client-centric approach. “Myonex looks forward to combining with our Creapharm colleagues to meet the needs of our clients with agility and speed,” Lovett stated, underscoring the synergistic potential of the acquisition.
Echoing Lovett’s sentiments, Eric Placet, Creapharm’s CEO and Founder, expressed enthusiasm for the merger’s ability to enhance service offerings and foster more efficient, patient-centric clinical trials. “Growing with Myonex is an obvious step for Creapharm,” Placet remarked, noting the mutual benefits of pooling resources and expertise.
The transaction, which awaits regulatory approval, signals not just a merger of services but a fusion of corporate cultures and values. Michael Cohen, Co-Owner and Executive Chairman of Myonex, highlighted the cultural and philosophical alignment between the two companies, particularly in terms of entrepreneurship, team engagement, and a shared commitment to social and environmental responsibility.
Upon completion of the deal, the leadership structure will see continuity and integration, with Mike Cohen continuing as Executive Chairman and James Lovett as CEO of the newly combined entity. Eric Placet will not only reinvest in Myonex but also join its Board of Directors, solidifying the strategic partnership. Additionally, key figures from Creapharm, including Carla Da Costa, will join the combined management teams, ensuring a seamless transition and continued innovation.
This acquisition represents a strategic leap forward for Myonex, promising to deliver enhanced scale, flexibility, and comprehensive solutions to meet the evolving needs of clients in the clinical trial sector worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.